Robbie Cano, dontcha know … not to do PEDs?
Mets second baseman Robinson Canó has been banged with a season-long suspension in 2021 after testing positive for a performance-enhancing drug, per an MLB release.
Canó, who served an 80-game suspension after testing positive for a banned substance in 2018, was dinged this time for his use of Stanozolol, per MLB's release, a separate drug than he used in 2018.
Stanozolol, what Canó tested positive for, is also what Rafael Palmeiro tested positive for 15 years ago. It hasn't been as common among PEDs findings in recent years, and is considered to be a highly detectable compared to newer PEDs.
— Eric Fisher (@EricFisherSBG) November 18, 2020
MORE: MLB free-agent tracker for 2020-21 offseason
Canó had a solid year for the Mets in 2020, hitting .316 with 10 home runs through 49 games.
While Canó was likely on his way to an eventual Cooperstown enshrinement, the dual suspensions should pretty much put the nail in the coffin of whatever Hall of Fame hopes Canó may have had.
Traded to New York after the 2018 season alongside Edwin Díaz, Canó has two more years under contract with the Mets following the 2021 season, both at a $24 million per year clip. He signed a 10-year, $240 million pact with the Mariners after the 2013 season.
Canó was set to earn $24 million this season with the Mets, but now forgoes that salary because of the suspension, leaving a very interesting question: What do the Mets do with the money Canó was set to earn?
Well, there is a very talented free-agent second baseman who played two season in New York already, but with the American League team. If new owner Steve Cohen doesn't go that route, then Jeff McNeil could slot back into the everyday second base role.
The Mets have options there, while Canó, unfortunately does not.
